The U.S. Food and Drug Administration announced on Friday that it has officially approved Miplyffa (arimoclomol) capsules, establishing the first medical therapy approved in the United States to treat neurological manifestations of Niemann-Pick disease type C (NPC).

Niemann-Pick type C is an ultra-rare, inherited lysosomal storage disorder that severely disrupts the body's ability to transport cholesterol and other lipids within cells. The abnormal accumulation of lipids leads to relentless, progressive neurological deterioration, impairing speech, cognition, swallowing, and motor coordination. Because symptoms frequently appear in early childhood, the condition is often characterized as 'childhood Alzheimer's.'

A Breakthrough for a Devastating Genetic Disorder

Miplyffa is indicated for use in combination with miglustat for adult and pediatric patients aged 2 years and older. By stimulating heat shock proteins, the drug helps cellular chaperone mechanisms clear toxic protein aggregates and stabilize impaired cellular homeostasis.

The approval was supported by data from a randomized, double-blind, placebo-controlled 12-month trial. Patients treated with Miplyffa experienced a statistically significant reduction in disease progression compared to those on placebo, as measured by the 4-Domain NPC Clinical Severity Scale assessing ambulation, speech, swallowing, and fine motor skills.

“NPC is a devastating, life-threatening condition that robs children and adults of vital motor and cognitive functions. Today's approval represents a long-awaited breakthrough for patients and families.”

Clinical Trial Evidence and Combined Mechanism of Action

Patient advocacy organizations and families who campaigned for decades hailed the milestone as a monumental victory. Untreated patients with early infantile or juvenile onset frequently succumb to aspiration pneumonia or severe neurological complications before reaching adulthood.

Manufacturer Zevra Therapeutics announced that comprehensive patient support programs will be activated immediately to ensure rapid commercial access, reimbursement navigation, and specialized distribution across pediatric neurology centers.

Sources

FDA Miplyffa Niemann-Pick Type C Rare Diseases Neurology Medicine